share_log

Format Therapeutics Provides 2021 Priorities

Benzinga Real-time News ·  Jan 11, 2021 20:15

Strong pipeline progress in 2020 positions company well for 2021

Established proof of concept in SCD for FT-4202

Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML

Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants

Completed successful IPO and follow-on equity offering

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment